Company profile
Amygdala Neuroscience company profile
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies. Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders.
Business identity
- Website
- http://www.amygns.com/
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $1M-$10M
- Founded
- 2015-01-01, Year
Headquarters
- Headquarters
- Saxeville, Wisconsin, United States
- Postal code
- 94301
- Country code
- US
- Continent
- North America